Modulation of COX2 and hTERT expression by photodynamic therapy in human colon cancer cells

Photodynamic therapy (PDT) was employed as a cancer therapy with photosensitizer (PS)-loaded cancer cells, eradicated by the reactive oxygen species after light activation. Cyclo-oxygenase 2 (COX2) is an enzyme expressed in 80% of colon adenocarcinoma and is one of the targets for effective cancer treatment. There is also uprising evidence that the human telomerase reverse transcriptase (hTERT), a catalytic component of telomerase, is reported as a promising indicator for monitoring cancer treatment. In this study, NPe6 mediated PDT on COX2 induced apoptosis in HT-29 was investigated. The cell cycle changes was analysed by flow cytometry and the hTERT expression at pre and post PDT was evaluated at transcription level by Taqman real time PCR. NPe6-PDT in HT-29 cells demonstrated anti-proliferating effect in a drug and light dose dependent manner. LD50 was achieved at 16μg/mL and 2J/cm2 at 4 hour-post treatment with a significant down-regulation of COX2 expression at LD30 and LD50 by immunohistochemical staining (IHC) (p<0.05, One-Way ANOVA). Membrane blebbing was detected in over 60% of cells. 35.2% of treated cells arrested in S-phase at LD50 after 24 hours by flow cytometry. A 0.25- and 0.6-fold down-regulation of hTERT mRNA expression was achieved at LD30 and LD50 respectively by TaqMan real-time PCR. To summarize, NPe6 mediated PDT down-regulated COX2 expression and triggered cell apoptosis. The hTERT can serve as an indicative marker for monitoring NPe6-PDT cancer treatment efficacy.

[1]  T. Vogl,et al.  A multicenter Phase I safety study of intratumoral photoactivation of talaporfin sodium in patients with refractory solid tumors , 2003, Cancer.

[2]  R. DuBois,et al.  COX-2: a molecular target for colorectal cancer prevention. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  I Vergote,et al.  A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group. , 1997, Journal of clinical pathology.

[4]  N. Mak,et al.  Cellular uptake, subcellular localization and photodamaging effect of temoporfin (mTHPC) in nasopharyngeal carcinoma cells: comparison with hematoporphyrin derivative. , 2000, Cancer letters.

[5]  T. Albertson,et al.  Pharmacokinetics and clinical effects of mono‐l‐aspartyl chlorin e6 (NPe6) photodynamic therapy in adult patients with primary or secondary cancer of the skin and mucosal surfaces , 2005, Photodermatology, photoimmunology & photomedicine.

[6]  T. Kaneko,et al.  Detection of photodynamic therapy-induced early apoptosis in human salivary gland tumor cells in vitro and in a mouse tumor model. , 2004, Oral oncology.

[7]  T. Wieman,et al.  Photodynamic therapy using mono-L-aspartyl chlorin e6 (Npe6) for the treatment of cutaneous disease: a Phase I clinical study. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  D. Kessel,et al.  DETERMINANTS OF PHOTOSENSITIZATION BY MONO‐L‐ASPARTYL CHLORIN e6 , 1989, Photochemistry and photobiology.

[9]  R. Ho,et al.  Effects of photoactivated 5-aminolevulinic acid hexyl ester on MDR1 over-expressing human uterine sarcoma cells. , 2008, Toxicology letters.

[10]  C. Gomer,et al.  Cyclooxygenase-2 inhibitor treatment enhances photodynamic therapy-mediated tumor response. , 2002, Cancer research.

[11]  D. Kessel,et al.  Determinants of the Apoptotic Response to Lysosomal Photodamage , 2000, Photochemistry and photobiology.

[12]  J. Prehn,et al.  Apoptosis signaling proteins as prognostic biomarkers in colorectal cancer: a review. , 2009, Biochimica et biophysica acta.

[13]  Hiroshi Nakamura,et al.  Morphologic evaluation of the antitumor activity of photodynamic therapy (PDT) using mono-L-aspartyl chlorin e6 (NPe6) against uterine cervical carcinoma cell lines , 2002, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[14]  A. Kato,et al.  Review article: COX-2, prostanoids and colon cancer. , 2002, Alimentary pharmacology & therapeutics.

[15]  M W Berns,et al.  In vitro photosensitization I. Cellular uptake and subcellular localization of mono‐L‐aspartyl chlorin e6, chloro‐aluminum sulfonated phthalocyanine, and photofrin II , 1989, Lasers in surgery and medicine.

[16]  Zheng Huang,et al.  Combination of Photodynamic Therapy and Immunomodulation: Current Status and Future Trends , 2008 .

[17]  J. Metz,et al.  Endobronchial photodynamic therapy for the treatment of lung cancer. , 2001, Chest surgery clinics of North America.

[18]  A. Grothey Biological Therapy and Other Novel Therapies in Early-Stage Disease: Are They Appropriate? , 2007, Clinical Cancer Research.

[19]  Maohui Luo,et al.  The telomerase activity and expression of hTERT gene can serve as indicators in the anti-cancer treatment of human ovarian cancer. , 2007, European journal of obstetrics, gynecology, and reproductive biology.

[20]  C. M. Yow,et al.  Photodynamic effect in medulloblastoma: downregulation of matrix metalloproteinases and human telomerase reverse transcriptase expressions , 2008, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.

[21]  L. Kèlland,et al.  Telomerase: biology and phase I trials. , 2001, The Lancet. Oncology.

[22]  J. Usuda,et al.  Photodynamic therapy (PDT) for lung cancers. , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[23]  R. Demir,et al.  Ultrastructural and immunohistochemical analysis of rat uroepithelial cell junctions after partial bladder outlet obstruction and selective COX-2 inhibitor treatment. , 2006, Acta histochemica.

[24]  C J Gomer,et al.  Metabolic properties and photosensitizing responsiveness of mono-L-aspartyl chlorin e6 in a mouse tumor model. , 1992, Cancer research.

[25]  Thomas J. Dougherty,et al.  Basic principles of photodynamic therapy , 2001 .

[26]  K. Imai,et al.  Increased cyclooxygenase-2 expression in large flat colorectal tumors (laterally spreading tumors) , 2003, Journal of Gastroenterology.

[27]  Q. Qi,et al.  Inhibition of human telomerase reverse transcriptase gene expression by gambogic acid in human hepatoma SMMC-7721 cells. , 2006, Life sciences.

[28]  C. Gomer,et al.  CHOP activation by photodynamic therapy increases treatment induced photosensitization , 2004, Lasers in surgery and medicine.

[29]  A. Zinsmeister,et al.  Mono‐L‐aspartyl chlorin e6 (NPe6) and hematoporphyrin derivative (HpD) in photodynamic therapy administered to a human cholangiocarcinoma model , 1998, Cancer.